Zacks Research Has Bullish Estimate for IQVIA Q4 Earnings

IQVIA Holdings Inc. (NYSE:IQV) – Equities research analysts at Zacks Research boosted their Q4 2025 earnings per share estimates for shares of IQVIA in a report issued on Tuesday, February 25th. Zacks Research analyst R. Department now expects that the medical research company will post earnings of $3.05 per share for the quarter, up from their prior estimate of $2.86. The consensus estimate for IQVIA’s current full-year earnings is $10.84 per share. Zacks Research also issued estimates for IQVIA’s Q3 2026 earnings at $3.24 EPS.

IQV has been the topic of several other reports. Leerink Partners reiterated an “outperform” rating and issued a $248.00 price target (down from $260.00) on shares of IQVIA in a report on Tuesday, November 19th. UBS Group reduced their target price on IQVIA from $260.00 to $255.00 and set a “buy” rating on the stock in a research note on Friday, February 7th. William Blair reiterated an “outperform” rating on shares of IQVIA in a research report on Wednesday, December 11th. Deutsche Bank Aktiengesellschaft cut their price target on shares of IQVIA from $270.00 to $265.00 and set a “buy” rating on the stock in a report on Friday, November 1st. Finally, The Goldman Sachs Group decreased their price objective on shares of IQVIA from $280.00 to $250.00 and set a “buy” rating for the company in a report on Friday, November 1st. Four investment analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $251.22.

IQVIA Stock Performance

IQVIA stock opened at $188.89 on Thursday. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. The firm has a market capitalization of $33.26 billion, a P/E ratio of 25.19, a price-to-earnings-growth ratio of 1.99 and a beta of 1.48. IQVIA has a 1-year low of $184.66 and a 1-year high of $261.73. The company’s 50-day moving average is $199.13 and its 200 day moving average is $214.96.

IQVIA (NYSE:IQV) last announced its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%.

Insider Buying and Selling

In other IQVIA news, Director John G. Danhakl bought 1,275 shares of the company’s stock in a transaction dated Tuesday, December 3rd. The shares were purchased at an average cost of $200.58 per share, for a total transaction of $255,739.50. Following the transaction, the director now directly owns 1,275 shares of the company’s stock, valued at approximately $255,739.50. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. 1.60% of the stock is currently owned by insiders.

Hedge Funds Weigh In On IQVIA

A number of hedge funds have recently bought and sold shares of the business. Smith Group Asset Management LLC purchased a new position in shares of IQVIA during the 4th quarter valued at approximately $1,616,000. Simplify Asset Management Inc. increased its stake in shares of IQVIA by 67.8% during the third quarter. Simplify Asset Management Inc. now owns 9,637 shares of the medical research company’s stock worth $2,284,000 after purchasing an additional 3,894 shares in the last quarter. Nordea Investment Management AB boosted its holdings in IQVIA by 47.4% in the 4th quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock worth $277,908,000 after buying an additional 452,029 shares during the last quarter. Hickory Asset Management Inc. acquired a new position in shares of IQVIA during the fourth quarter valued at approximately $941,000. Finally, Fifth Third Bancorp lifted its position in shares of IQVIA by 13.0% in the fourth quarter. Fifth Third Bancorp now owns 13,179 shares of the medical research company’s stock valued at $2,590,000 after acquiring an additional 1,521 shares in the last quarter. Hedge funds and other institutional investors own 89.62% of the company’s stock.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.